• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于在无症状HBsAg血清阳性个体中识别早期肝细胞癌的液体活检检测方法。

A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals.

作者信息

Qu Chunfeng, Jiao Yuchen, Wang Yuting

机构信息

State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Mol Cell Oncol. 2019 May 28;6(5):e1614419. doi: 10.1080/23723556.2019.1614419. eCollection 2019.

DOI:10.1080/23723556.2019.1614419
PMID:31528693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6736321/
Abstract

Biannual screening of hepatocellular carcinoma (HCC) by ultrasonography and serum α-fetoprotein has been proposed to the HBsAg-seropositive individuals. The widespread application to all of them was restricted due to limited acceptability of resource and anxiety-producing procedures. We recently developed a novel liquid biopsy assay to identify HCC cases in asymptomatic HBsAg-positive individuals.

摘要

已建议对乙肝表面抗原血清阳性个体每半年进行一次超声检查和血清甲胎蛋白检测以筛查肝细胞癌(HCC)。由于资源可接受性有限以及检查程序会引发焦虑,因此无法将该检查广泛应用于所有此类个体。我们最近开发了一种新型液体活检检测方法,用于识别无症状乙肝表面抗原阳性个体中的肝癌病例。

相似文献

1
A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals.一种用于在无症状HBsAg血清阳性个体中识别早期肝细胞癌的液体活检检测方法。
Mol Cell Oncol. 2019 May 28;6(5):e1614419. doi: 10.1080/23723556.2019.1614419. eCollection 2019.
2
Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.液体活检在肝细胞癌中作为预后和预测生物标志物的临床应用:循环肿瘤细胞和循环肿瘤 DNA。
J Exp Clin Cancer Res. 2018 Sep 3;37(1):213. doi: 10.1186/s13046-018-0893-1.
3
Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma.HBsAg阳性和HBsAg阴性患者血清甲胎蛋白在肝细胞癌诊断中的特异性
Hepatology. 1991 Jul;14(1):68-72. doi: 10.1002/hep.1840140112.
4
[Community-based hepatocellular carcinoma screening in seven townships in Taiwan].
J Formos Med Assoc. 1995 Dec;94 Suppl 2:S94-102.
5
Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area.在乙型肝炎和丙型肝炎流行地区,对老年居民进行基于社区的肝细胞癌筛查。
J Gastroenterol Hepatol. 2011 Jan;26(1):129-34. doi: 10.1111/j.1440-1746.2010.06476.x.
6
Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes.
J Hepatol. 1994 Mar;20(3):398-404. doi: 10.1016/s0168-8278(94)80015-4.
7
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.纳入血清乙肝表面抗原水平或省略乙肝病毒DNA水平不影响无肝硬化患者肝细胞癌风险的计算。
Clin Gastroenterol Hepatol. 2016 Mar;14(3):461-468.e2. doi: 10.1016/j.cgh.2015.10.033. Epub 2015 Nov 18.
8
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.代偿期病毒性肝硬化患者肝细胞癌的发病率
Cancer. 1999 May 15;85(10):2132-7.
9
Liquid Biopsy in Hepatocellular Carcinoma肝细胞癌中的液体活检
10
Alpha-fetoprotein synthesis in human hepatocellular carcinoma: correlation with hepatitis B surface antigen expression.
Cancer Invest. 1992;10(6):513-22. doi: 10.3109/07357909209024813.

本文引用的文献

1
Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy.液体活检在无症状 HBsAg 阳性个体中早期检测肝细胞癌。
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6308-6312. doi: 10.1073/pnas.1819799116. Epub 2019 Mar 11.
2
Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China.肝癌大规模筛查:来自中国中山市示范筛查项目的结果。
Sci Rep. 2018 Aug 24;8(1):12787. doi: 10.1038/s41598-018-31119-9.
3
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南:肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
4
Detection and localization of surgically resectable cancers with a multi-analyte blood test.通过多分析物血液检测对外科可切除癌症进行检测和定位。
Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.
5
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.循环肿瘤 DNA 甲基化标志物用于肝细胞癌的诊断和预后。
Nat Mater. 2017 Nov;16(11):1155-1161. doi: 10.1038/nmat4997. Epub 2017 Oct 9.
6
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.《亚太地区肝细胞癌管理临床实践指南:2017年更新版》
Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15.
7
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
8
Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas.在肝炎高发地区评估甲胎蛋白作为肝细胞癌筛查标志物的作用。
Ann Hepatol. 2015 Nov-Dec;14(6):882-8. doi: 10.5604/16652681.1171776.
9
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.肝细胞癌的遗传景观和生物标志物。
Gastroenterology. 2015 Oct;149(5):1226-1239.e4. doi: 10.1053/j.gastro.2015.05.061. Epub 2015 Jun 20.
10
Randomized controlled trial of screening for hepatocellular carcinoma.肝细胞癌筛查的随机对照试验
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22. doi: 10.1007/s00432-004-0552-0.